This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Bionomics Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Spyros Papapetropoulos

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	n/a
Management average tenure	less than a year
Board average tenure	3yrs

Recent management updates

Recent updates

CEO

Spyros Papapetropoulos (50 yo)

less than a year

Tenure

Dr. Spyridon Papapetropoulos, M. D., Ph. D., also known as Spyros, serves as Director, President & Chief Executive Officer at Bionomics Limited from January 05, 2023. He serves as Member of Scientific Advi...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Adrian Hinton	Financial Controller	less than a year	AU$323.78k	0.0048% A$ 305.4
Spyridon Papapetropoulos	CEO, President & Director	less than a year	no data	no data
Timothy Cunningham	Chief Financial Officer	less than a year	no data	no data
Paul Rolan	Consultant Chief Medical Officer of Clinical Neuroscience	no data	AU$102.00k	no data
Julie Kerner	Senior Vice President of Business Operations	less than a year	no data	no data
Atul Mahableshwarkar	Acting Chief Medical Officer	less than a year	no data	no data
Suzanne Irwin	Company Secretary	2.4yrs	no data	no data

0.3yrs

Average Tenure

60yo

Average Age

Experienced Management: B1N's management team is not considered experienced ( 0.3 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Spyridon Papapetropoulos	CEO, President & Director	less than a year	no data	no data
Errol B. De Souza	Non-Executive Director	15.6yrs	AU$4.03m	0.025% A$ 1.6k
David Wilson	Independent Non-Executive Director	7.3yrs	AU$87.00k	0.017% A$ 1.1k
Alan Fisher	Independent Non-Executive Chair of the Board	7yrs	AU$87.00k	0.0068% A$ 436.1
Jane Ryan	Independent Non-Executive Director	2.9yrs	AU$93.15k	0% A$ 0
Srinivas Rao	Member of Clinical Advisory Board	1.9yrs	AU$57.75k	no data
Murray Stein	Member of Clinical Advisory Board	no data	no data	no data
Steven Williams	Scientific Advisor	no data	no data	no data
Allan Young	Scientific Advisor	no data	no data	no data
Marina Picciotto	Scientific Advisor	no data	no data	no data
Peter Miles Davies	Independent Non-Executive Director	2.2yrs	AU$77.00k	0.018% A$ 1.2k
Aaron N. Weaver	Independent Non-Executive Nominee Director	3.2yrs	AU$77.00k	no data

3.0yrs

Average Tenure

56.5yo

Average Age

Experienced Board: B1N's board of directors are considered experienced (3 years average tenure).

This company listing is no longer active

Bionomics Management

Management criteria checks 1/4

Key information

Recent management updates

Bionomics Limited Appoints Tim Cunningham as Chief Financial Officer

High number of new directors

High number of new and inexperienced directors

Bionomics Limited, Annual General Meeting, Nov 16, 2022

High number of new and inexperienced directors

High number of new and inexperienced directors

Recent updates

New minor risk - Financial data availability

Bionomics Completes Last Patient Last Visit in the Phase 2B Attune Study for Post-Traumatic Stress Disorder

New major risk - Market cap size

Bionomics Limited Appoints Tim Cunningham as Chief Financial Officer

First half 2023 earnings released: AU$0.012 loss per share (vs AU$0.013 loss in 1H 2022)

High number of new directors

Bionomics Limited Reports Results in PREVAIL Phase2 Study BNC210

High number of new and inexperienced directors

Bionomics Limited, Annual General Meeting, Nov 16, 2022

Full year 2022 earnings released: AU$0.016 loss per share (vs AU$0.011 loss in FY 2021)

High number of new and inexperienced directors

High number of new and inexperienced directors

Bionomics Limited announced that it has received $2.794495 million in funding

Bionomics Initiates Phase 2 Prevail Study of Bnc210 for the Acute Treatment of Social Anxiety Disorder

High number of new directors

U.S. Food and Drug Administration Grants Bionomics Fast Track Designation to Bnc210 for the Acute Treatment of Social Anxiety Disorder and Other Anxiety Related Disorders

Bionomics Prepares BNC210 for Start of Phase 2 Acute Treatment of Social Anxiety Disorder Trial

Full year 2021 earnings released: AU$0.01 loss per share (vs AU$0.011 loss in FY 2020)

Bionomics Initiates Phase 2B ATTUNE Study of BNC210 in PTSD

Bionomics BNC210 Expansion into Social Anxiety Disorder

Legal Counsel & Company Secretary has left the company

Revenue beats expectations

Bionomics Limited has completed a Follow-on Equity Offering in the amount of AUD 15.991634 million.

Bionomics Limited Announces Positive BNC210 PK Results for Solid Dose Formulation

New 90-day high: €0.27

Bionomics Limited and EmpathBio Inc Joint Feasibility Assessment

Bionomics Limited announced that it expects to receive AUD 15.991634 million in funding

Bionomics Limited Completes Treatment Phase in the MODULATE Clinical Trial

Bionomics Limited Announces Publication of Positive BNC210 Phase 2a Data in Gad Patients

Bionomics Limited Initiates 7-Day Dosing Pharmacokinetic Study of BNC210

Bionomics Limited Licenses Drug Candidate BNC101 to Carina Biotech

Bionomics Limited Announces Director Changes

Bionomics Limited announced that it has received AUD 5.43332 million in funding from Apeiron Investment Group Ltd. and other investors

Full year earnings released - €0.0082 loss per share

CEO

Tenure

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age